Corcept Therapeutics
Nasdaq CORT · Redwood City, CA
Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Metabolic & endocrine · Neurology · Oncology · Renal & urogenital · Women's health
Corcept Therapeutics is a clinical trial sponsor based in Redwood City, CA, listed as Nasdaq CORT. It has 6 active clinical trials with 1,185 planned participants, across 9 therapeutic areas. Since 2021 it has completed 32 trials and stopped 3 early.
Trial track record · since 2021
Financials · Nasdaq CORT
Pipeline · 6 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
2 approved drug applications with a product on the market.
Questions about Corcept Therapeutics
Corcept Therapeutics is lead sponsor of 6 active clinical trials on ClinicalTrials.gov, with 1,185 planned participants, in Cardiovascular, Dermatology, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 32 trials and stopped 3 early.
Corcept Therapeutics is based in Redwood City, CA and is listed as Nasdaq CORT. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Corcept Therapeutics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
Approve Suite is not affiliated with Corcept Therapeutics. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.